BridgeBio Pharma (BBIO) Share-based Compensation (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Share-based Compensation data on file, last reported at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 84.26% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$11.1 million (down 114.62% YoY), and the FY2025 full-year result was $14.2 million, down 35.92% from the prior year.
• Share-based Compensation improved to $4.1 million in Q1 2026, from -$84.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $37.3 million in Q2 2025 to a low of -$84.2 million in Q4 2025.
• A 5-year average of $9.8 million and a median of $18.7 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 18078.81% in 2024 and slumped 6094.23% in 2025, its largest moves.
• Tracing BBIO's Share-based Compensation over 5 years: stood at $22.6 million in 2022, then jumped by 36.5% to $30.8 million in 2023, then slumped by 95.45% to $1.4 million in 2024, then tumbled by 6094.23% to -$84.2 million in 2025, then soared by 104.84% to $4.1 million in 2026.
• Business Quant data shows BBIO's Share-based Compensation at $4.1 million in Q1 2026, -$84.2 million in Q4 2025, and $31.7 million in Q3 2025.